Christopher J. Kenney's most recent trade in Xenon Pharmaceuticals Inc was a trade of 3,750 Common Shares done . Disclosure was reported to the exchange on March 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 3,750 | 8,479 (0%) | 0% | - | Common Shares | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 3,750 | 11,250 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.22 per share. | 12 Mar 2026 | 1,410 | 7,069 (0%) | 0% | 55.2 | 77,867 | Common Shares |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 7,500 | 7,500 (0%) | 0% | - | Common Shares | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 7,500 | 0 | - | - | Performance Share Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2026 | 7,500 | 7,500 | - | - | Performance Share Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.11 per share. | 09 Mar 2026 | 2,771 | 4,729 (0%) | 0% | 60.1 | 166,559 | Common Shares |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 100,000 | 100,000 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 20,000 | 20,000 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 80,000 | 80,000 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 15,000 | 15,000 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 24 Mar 2023 | 700 | 0 (0%) | 0% | 35.0 | 24,507 | Common Shares |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Hallmark Financial Service... | Christopher J. Kenney | President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2022 | 51,654 | 51,654 | - | - | Restricted Stock Units | |
| Hallmark Financial Service... | Christopher J. Kenney | President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2022 | 45,724 | 45,724 | - | - | Restricted Stock Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 28.81 per share. | 21 Jan 2022 | 700 | 700 (0%) | 0% | 28.8 | 20,167 | Common Shares |
| Hallmark Financial Service... | Christopher J. Kenney | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 45,724 | 45,724 | - | - | Restricted Stock Units | |
| Xenon Pharma Inc | Christopher John Kenney | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |